Benzinga | Jan 8, 2021 07:29AM EST

Wells Fargo Downgrades Amphastar Pharmaceuticals to Equal-Weight, Announces $21 Price Target

Wells Fargo analyst Jacob Hughes downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) from Overweight to Equal-Weight and announces $21 price target.